Davita Healthcare Partners Inc (DVA) Stock Price, Quote & News

Company Profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administ...

Industry: Medical Care Facilities

Sector: Healthcare

Phone: 720 631 2100

Website: www.davita.com

Address:

2000 16th Street, Denver, United States

Noname2022 Mar. 20 at 8:24 PM

$AKBA $CRMD $FMS $DVA https://www.kidneyfund.org/article/american-kidney-fund-statement-us-house-ways-means-health-subcommittee-hearing-improving-kidney

0 · Reply

Noname2022 Mar. 20 at 12:15 AM

$AKBA $CRMD $FMS $DVA

0 · Reply

Noname2022 Mar. 19 at 7:55 PM

$CRMD $AKBA $DVA $FMS Akebia’s House documents… Defencath reduced CBRSIs by 71%! https://docs.house.gov/meetings/WM/WM02/20260318/119076/HHRG-119-WM02-Wstate-ButlerJ-20260318.pdf

1 · Reply

Noname2022 Mar. 18 at 9:41 PM

$AKBA $CRMD $FMS $DVA https://nonprofitkidneycare.org/wp-content/uploads/2026/03/NKCA-WM-Hearing-Press-Release-v.4.pdf

0 · Reply

Noname2022 Mar. 18 at 9:11 PM

$CRMD $AKBA $FMS $DVA

0 · Reply

Noname2022 Mar. 18 at 5:29 PM

$CRMD $AKBA $FMS $DVA https://kidneycarepartners.org/press/kidney-care-partners-praises-bipartisan-house-committee-on-ways-and-means-health-subcommittee-leaders-for-efforts-to-improve-kidney-health-through-better-prevention-and-innovative-treatment/

0 · Reply

Noname2022 Mar. 18 at 2:36 PM

$CRMD $AKBA $FMS $DVA

1 · Reply

Noname2022 Mar. 17 at 11:58 PM

$CRMD $AKBA $DVA $FMS https://waysandmeans.house.gov/event/health-subcommittee-hearing-on-improving-kidney-health-through-better-prevention-and-innovative-treatment/

1 · Reply

Noname2022 Mar. 17 at 8:45 PM

$AKBA $CRMD $DVA $FMS

1 · Reply

Noname2022 Mar. 17 at 2:12 PM

$AKBA $CRMD $DVA $FMS Witnesses for tomorrow’s hearing… https://admin-waysandmeans.house.gov/event/health-subcommittee-hearing-on-improving-kidney-health-through-better-prevention-and-innovative-treatment/

2 · Reply

DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

Mar 17, 2026, 7:00 AM EDT - 4 days ago

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

Mar 2, 2026, 2:07 PM EST - 19 days ago

DaVita Inc. (DVA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Feb 24, 2026, 2:00 PM EST - 25 days ago

DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference

Feb 11, 2026, 10:45 AM EST - 5 weeks ago

20 stocks of companies that delivered a double dose of growth this earnings season

APH BA CAH FICO GLW GOOG GOOGL

Feb 3, 2026, 12:25 PM EST - 6 weeks ago

DaVita Stock Rallies On Profit Beat, Confident 2026 View

Feb 3, 2026, 11:00 AM EST - 6 weeks ago

TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings

PEP TER

Feb 3, 2026, 10:30 AM EST - 6 weeks ago

DaVita: Some Success Is Possible, But Volatility Is Still Heavy

Feb 2, 2026, 7:30 PM EST - 6 weeks ago

DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript

Feb 2, 2026, 5:06 PM EST - 6 weeks ago

DaVita forecasts 2026 profit above estimates on steady dialysis service demand; shares jump

Feb 2, 2026, 4:05 PM EST - 6 weeks ago

DaVita Inc. 4th Quarter 2025 Results

Jan 21, 2026, 10:00 AM EST - 2 months ago

DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call

Dec 11, 2025, 8:00 AM EST - 3 months ago

DaVita Names New Leaders to Accelerate Care Transformation

Dec 3, 2025, 9:30 AM EST - 3 months ago

DaVita: More Volatile But Better Upside Than Fresenius

Nov 17, 2025, 1:57 PM EST - 4 months ago

DaVita Inc. (DVA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 14, 2025, 4:16 PM EST - 4 months ago

DaVita Inc. to Participate in Fireside Chat with Wolfe Research

Nov 4, 2025, 8:00 AM EST - 4 months ago

DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025

Oct 29, 2025, 7:46 PM EDT - 5 months ago

DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 5:32 PM EDT - 5 months ago

DaVita misses quarterly profit estimates on rising costs, lower volumes

Oct 29, 2025, 4:05 PM EDT - 5 months ago

DaVita Inc. 3rd Quarter 2025 Results

Oct 20, 2025, 8:00 AM EDT - 5 months ago

DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives

Oct 13, 2025, 2:00 PM EDT - 5 months ago

DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call

Aug 27, 2025, 8:00 AM EDT - 7 months ago

DaVita Honors 25 Years of Clinical Advancement in Chronic Disease Care

Aug 21, 2025, 5:59 PM EDT - 7 months ago

Ransomware attack at dialysis firm DaVita affects 2.7 million people, US health dept website shows

Aug 20, 2025, 9:36 AM EDT - 7 months ago

DaVita: Aggressive Buybacks Despite Rising Cost Of Debt

Aug 5, 2025, 10:02 PM EDT - 8 months ago

DaVita Inc. (DVA) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 5:15 PM EDT - 8 months ago

DaVita beats quarterly profit on steady demand for dialysis services

Aug 5, 2025, 4:05 PM EDT - 8 months ago

DaVita Inc. 2nd Quarter 2025 Results

Jul 17, 2025, 5:37 PM EDT - 8 months ago

DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call

Jun 2, 2025, 12:15 PM EDT - 10 months ago

20 stocks primed for rapid growth while trading at half of Nvidia's valuation

AIG APTV BALL CTRA DELL ELV EQT

May 30, 2025, 2:35 PM EDT - 10 months ago

DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates

May 27, 2025, 11:30 AM EDT - 10 months ago

DaVita: International Expansion And Buybacks Will Boost Returns

May 20, 2025, 4:42 PM EDT - 10 months ago

DaVita Inc. Announces Upsize and Pricing of $1 Billion Senior Notes Offering

May 20, 2025, 9:05 AM EDT - 10 months ago

DaVita Releases Annual Community Care Report, Highlights Achievements in Corporate Citizenship

May 20, 2025, 8:51 AM EDT - 10 months ago

DaVita Inc. Announces Offering of $750 Million Senior Notes

May 12, 2025, 9:41 PM EDT - 11 months ago

DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript

May 12, 2025, 5:37 PM EDT - 11 months ago

DaVita beats quarterly profit estimates amid stable demand for dialysis services

May 12, 2025, 4:51 PM EDT - 11 months ago

DaVita First-Quarter 2025 Financial Results: Just the Numbers

May 12, 2025, 4:05 PM EDT - 11 months ago

DaVita Inc. 1st Quarter 2025 Results

Apr 30, 2025, 11:00 AM EDT - 11 months ago

DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

Apr 14, 2025, 7:35 AM EDT - 1 year ago

DaVita Says Ransomware Attack Affecting Some Operations

Apr 14, 2025, 7:33 AM EDT - 1 year ago

Dialysis firm DaVita hit by ransomware attack

Mar 31, 2025, 7:35 AM EDT - 1 year ago

These 15 stocks are the most profitable companies in the S&P 500

AAPL ABBV AON BA CL CLX COR

Mar 6, 2025, 10:00 AM EST - 1 year ago

DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2025

Feb 27, 2025, 9:00 AM EST - 1 year ago

YMCA of the USA Deepens Collaboration with DaVita to Drive Kidney Health Initiatives in Seven Communities

Feb 19, 2025, 8:05 PM EST - 1 year ago

Berkshire Hathaway sells another 750,000 DaVita shares

Feb 14, 2025, 1:01 PM EST - 1 year ago

DaVita's stock leads S&P 500 decliners after Berkshire pares stake. Its soft guidance isn't helping.

Feb 14, 2025, 8:16 AM EST - 1 year ago

Warren Buffett's Berkshire Hathaway sells some DaVita; Shares fall on disappointing guidance

Feb 13, 2025, 8:19 PM EST - 1 year ago

DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 8:13 PM EST - 1 year ago

Berkshire sells some DaVita shares, cuts stake to 45%

Noname2022 Mar. 20 at 8:24 PM

$AKBA $CRMD $FMS $DVA https://www.kidneyfund.org/article/american-kidney-fund-statement-us-house-ways-means-health-subcommittee-hearing-improving-kidney

0 · Reply

Noname2022 Mar. 20 at 12:15 AM

$AKBA $CRMD $FMS $DVA

0 · Reply

Noname2022 Mar. 19 at 7:55 PM

$CRMD $AKBA $DVA $FMS Akebia’s House documents… Defencath reduced CBRSIs by 71%! https://docs.house.gov/meetings/WM/WM02/20260318/119076/HHRG-119-WM02-Wstate-ButlerJ-20260318.pdf

1 · Reply

Noname2022 Mar. 18 at 9:41 PM

$AKBA $CRMD $FMS $DVA https://nonprofitkidneycare.org/wp-content/uploads/2026/03/NKCA-WM-Hearing-Press-Release-v.4.pdf

0 · Reply

Noname2022 Mar. 18 at 9:11 PM

$CRMD $AKBA $FMS $DVA

0 · Reply

Noname2022 Mar. 18 at 5:29 PM

0 · Reply

Noname2022 Mar. 18 at 2:36 PM

$CRMD $AKBA $FMS $DVA

1 · Reply

Noname2022 Mar. 17 at 11:58 PM

$CRMD $AKBA $DVA $FMS https://waysandmeans.house.gov/event/health-subcommittee-hearing-on-improving-kidney-health-through-better-prevention-and-innovative-treatment/

1 · Reply

Noname2022 Mar. 17 at 8:45 PM

$AKBA $CRMD $DVA $FMS

1 · Reply

Noname2022 Mar. 17 at 2:12 PM

2 · Reply

DonCorleone77 Mar. 17 at 11:31 AM

$DVA R1 Therapeutics launches with oversubscribed $77.5M Series A financing R1 Therapeutics announced its launch with an oversubscribed $77.5M Series A financing, along with the exclusive global license to develop and commercialize AP306 outside of Greater China from China-based Alebund Pharmaceuticals. The financing was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita, with participation from Curie.Bio, SymBiosis, and U.S. Renal Care. Proceeds from the Series A financing will fund R1's global development program of AP306 in partnership with Alebund, including a Phase 2b study planned to start later this year. AP306 is a first-in-class, pan phosphate transporter inhibitor in development as a monotherapy for the treatment of hyperphosphatemia in patients with chronic kidney disease. Whereas currently available approved phosphate lowering therapies work by inhibiting "passive" transport of phosphate through binding phosphate and other mechanisms, AP306 is distinguished as being the only agent that blocks the "active" transport of phosphate for the treatment of CKD.

0 · Reply

Noname2022 Mar. 14 at 6:50 PM

$CRMD $AKBA $FMS $DVA GovTrack currently shows about a 3% chance of enactment for the bill. Worth noting: Rep. Mike Kelly joined as a cosponsor on Jan 30 and sits on the House Ways & Means Health Subcommittee, the committee responsible for Medicare dialysis policy and the upcoming kidney hearing.

6 · Reply

Noname2022 Mar. 12 at 10:53 PM

$CRMD $AKBA $DVA $FMS

0 · Reply

SweStonk Mar. 6 at 9:47 PM

$CRMD I have never been more certain about the success of a drug like defencath. Within 10 years we will be SoC and everyone will use defencath. Less infections = cheaper costs Less infections = lower deaths RWE 70%, it is huge and TDAPA dip uncertainty wont last long. Dont let the bears fool you. BUY when others are fearful. Joe would NEVER announce share repurchase this early if he wasnt confident about defencaths future. This is a FUCKING gold mine at this price! $DVA $XBI $IBB

2 · Reply

ZacksResearch Mar. 6 at 6:48 PM

$DVA up 11.5% in 6 months — is it poised for more growth? 🚀 DaVita's solid Q4 results and projected overseas growth are driving optimism, with a Zacks Rank #2 (Buy). But keep an eye on its dependence on commercial payers. Discover the full investment picture here 👉 https://www.zacks.com/stock/news/2880351/heres-why-you-should-add-davita-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2880351-body-36468&ADID=SYND_STOCKTWITS_TWEET_2_2880351_BODY_36468

0 · Reply

ZacksResearch Mar. 6 at 5:48 PM

$DVA is back on investors’ radar after strong Q4 results — but there’s a catch. The company is drawing attention on solid quarterly performance and steady global expansion, though its heavy reliance on commercial insurers still raises a key risk to watch. ⚠️ See why the stock is getting fresh attention 👉 https://www.zacks.com/stock/news/2880351/heres-why-you-should-add-davita-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2880351-teaser-36410&ADID=SYND_STOCKTWITS_TWEET_2_2880351_TEASER_36410

0 · Reply

Noname2022 Mar. 5 at 2:32 PM

$AKBA $CRMD $DVA $FMS

0 · Reply

Noname2022 Mar. 5 at 1:14 AM

$AKBA $CRMD $DVA $FMS

1 · Reply

Noname2022 Mar. 4 at 7:55 PM

$CRMD $AKBA $FMS $DVA

2 · Reply

Noname2022 Mar. 2 at 11:06 PM

$AKBA $DVA $FMS

0 · Reply

Noname2022 Mar. 2 at 7:16 PM

$AKBA $CRMD $DVA $FMS Not TDAPA related, still bipartisan kidney related legislation advancing out of committee to the floor

0 · Reply

Noname2022 Feb. 27 at 10:23 PM

$CRMD $AKBA $DVA $FMS a kidney bill that made it out of committee https://www.kidneyfund.org/article/american-kidney-fund-applauds-bipartisan-committee-approval-living-donor-protection-act

0 · Reply

Market Cap	9.94B
Revenue (ttm)	13.64B
Net Income (ttm)	746.80M
EPS (ttm)	N/A
PE Ratio	13.70
Forward PE	10.51
Profit Margin	5.47%
Debt to Equity Ratio	-28.02

Volume	2,285,900
Avg Vol	1,177,644
Day's Range	N/A - N/A
Shares Out	66.80M
Stochastic %K	29%
Beta	0.94
Analysts	Sell
Price Target	$151.00